Raffles Medical Group Ltd (SGX:BSL)
Singapore
· Delayed Price · Currency is SGD 1.010
-0.010 (-0.99%)
Mar 26, 2025, 11:50 AM SGT
Raffles Medical Group Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 751.56 | 706.92 | 822.92 | 723.79 | 568.2 | Upgrade
|
| Other Revenue | - | 1.11 | 2.03 | 1.44 | - | Upgrade
|
| Revenue | 751.56 | 708.03 | 824.95 | 725.23 | 568.2 | Upgrade
|
| Revenue Growth (YoY) | 6.15% | -14.17% | 13.75% | 27.64% | 8.84% | Upgrade
|
| Cost of Revenue | 413.39 | 392.1 | 424.85 | 530.24 | 427.47 | Upgrade
|
| Gross Profit | 338.17 | 315.94 | 400.1 | 194.99 | 140.73 | Upgrade
|
| Selling, General & Admin | 168.47 | 142.02 | 109.2 | 5.44 | 5.38 | Upgrade
|
| Other Operating Expenses | 41.47 | 32 | 41.22 | 34.22 | 30.23 | Upgrade
|
| Operating Expenses | 253.08 | 207.76 | 186.83 | 76.79 | 69.67 | Upgrade
|
| Operating Income | 85.1 | 108.18 | 213.26 | 118.2 | 71.07 | Upgrade
|
| Interest Expense | -5.78 | -6.08 | -6.85 | -6.36 | -5.15 | Upgrade
|
| Interest & Investment Income | 10.25 | 9.76 | 2.74 | 0.63 | 1.15 | Upgrade
|
| EBT Excluding Unusual Items | 89.56 | 111.86 | 209.15 | 112.48 | 67.06 | Upgrade
|
| Impairment of Goodwill | -2.6 | - | -5.87 | -3.78 | -3.5 | Upgrade
|
| Asset Writedown | -0 | 7.4 | -12.03 | 0.41 | -4.5 | Upgrade
|
| Other Unusual Items | - | 0.18 | 0.08 | 6.47 | 25.38 | Upgrade
|
| Pretax Income | 86.96 | 119.44 | 191.34 | 115.58 | 84.44 | Upgrade
|
| Income Tax Expense | 24.68 | 28.35 | 47.94 | 31.87 | 19.77 | Upgrade
|
| Earnings From Continuing Operations | 62.28 | 91.09 | 143.4 | 83.72 | 64.67 | Upgrade
|
| Minority Interest in Earnings | -0.04 | -0.94 | -0.19 | 0.46 | 1.22 | Upgrade
|
| Net Income | 62.24 | 90.15 | 143.21 | 84.17 | 65.89 | Upgrade
|
| Net Income to Common | 62.24 | 90.15 | 143.21 | 84.17 | 65.89 | Upgrade
|
| Net Income Growth | -30.96% | -37.05% | 70.15% | 27.74% | 9.32% | Upgrade
|
| Shares Outstanding (Basic) | 1,857 | 1,859 | 1,857 | 1,868 | 1,839 | Upgrade
|
| Shares Outstanding (Diluted) | 1,861 | 1,869 | 1,866 | 1,876 | 1,840 | Upgrade
|
| Shares Change (YoY) | -0.41% | 0.12% | -0.54% | 1.96% | 1.35% | Upgrade
|
| EPS (Basic) | 0.03 | 0.05 | 0.08 | 0.05 | 0.04 | Upgrade
|
| EPS (Diluted) | 0.03 | 0.05 | 0.08 | 0.04 | 0.04 | Upgrade
|
| EPS Growth | -30.70% | -37.16% | 70.82% | 25.42% | 7.83% | Upgrade
|
| Free Cash Flow | 66.98 | 168.79 | 171.21 | 110.17 | 74.27 | Upgrade
|
| Free Cash Flow Per Share | 0.04 | 0.09 | 0.09 | 0.06 | 0.04 | Upgrade
|
| Dividend Per Share | 0.025 | 0.024 | 0.038 | 0.018 | 0.025 | Upgrade
|
| Dividend Growth | 4.17% | -36.84% | 111.11% | -28.00% | - | Upgrade
|
| Gross Margin | 45.00% | 44.62% | 48.50% | 26.89% | 24.77% | Upgrade
|
| Operating Margin | 11.32% | 15.28% | 25.85% | 16.30% | 12.51% | Upgrade
|
| Profit Margin | 8.28% | 12.73% | 17.36% | 11.61% | 11.60% | Upgrade
|
| Free Cash Flow Margin | 8.91% | 23.84% | 20.75% | 15.19% | 13.07% | Upgrade
|
| EBITDA | 125.85 | 132.89 | 239.72 | 143.3 | 94.23 | Upgrade
|
| EBITDA Margin | 16.74% | 18.77% | 29.06% | 19.76% | 16.58% | Upgrade
|
| D&A For EBITDA | 40.75 | 24.71 | 26.46 | 25.1 | 23.17 | Upgrade
|
| EBIT | 85.1 | 108.18 | 213.26 | 118.2 | 71.07 | Upgrade
|
| EBIT Margin | 11.32% | 15.28% | 25.85% | 16.30% | 12.51% | Upgrade
|
| Effective Tax Rate | 28.38% | 23.73% | 25.05% | 27.57% | 23.41% | Upgrade
|
Updated Feb 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.